Prelude Therapeutics, Inc. ((PRLD)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prelude Therapeutics, Inc. is conducting a Phase 1 clinical study titled A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination With Docetaxel in Participants With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation. The study aims to evaluate the safety, tolerability, and efficacy of PRT3789, a SMARCA2 degrader, in patients with advanced or metastatic solid tumors with SMARCA4 mutations. This research is significant as it explores a novel therapeutic approach for a challenging cancer subset.
The intervention involves testing PRT3789 both as a standalone treatment and in combination with Docetaxel. Both drugs are administered via intravenous infusion, targeting the degradation of SMARCA2 to combat tumor growth.
The study follows a non-randomized, sequential intervention model without masking, focusing primarily on treatment. This design allows for dose escalation to determine the maximum tolerated dose and recommended phase 2 dose, ensuring a thorough assessment of the drug’s potential.
Key dates for the study include its start on May 2, 2023, with the primary completion and estimated study completion expected by June 26, 2025. These timelines are crucial for tracking the study’s progress and anticipating future developments.
The market implications of this study update could be significant for Prelude Therapeutics, potentially boosting investor confidence and stock performance if results are favorable. The study’s focus on a novel therapeutic target may also influence the competitive landscape in oncology drug development.
The study is ongoing, with further details available on the ClinicalTrials portal.